Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06855095 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial(ATSA) | recruiting | Phase 2 / Phase 3 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05303714 | PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer(PIPAC_VEROne) | recruiting | Phase 3 | 98 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05955924 | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial(SPRINTR) | recruiting | Phase 3 | 396 | Women's College HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | recruiting | Phase 3 | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 6 | Jan 7, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | recruiting | Phase 3 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | recruiting | Phase 3 | 180 | Luye Pharma Group Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05919030 | A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 155 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06601335 | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | recruiting | Phase 3 | 510 | AkesoINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04447352 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)(PREVENT) | recruiting | Phase 3 | 200 | Krankenhaus NordwestOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06022861 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 510 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05582265 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) | recruiting | Phase 3 | 537 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | recruiting | Phase 3 | 354 | Fudan UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | recruiting | Phase 3 | 196 | Wen TianfuOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06247605 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | recruiting | Phase 3 | 243 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2025source: clinicaltrials